Clinical Trial Search

Primary: Number of Dose Limiting Toxicities (DLT) of IT Trastuzumab in Sequential Cohorts of Escalating Doses for Patients With Leptomeningeal Metastases in HER2+ Breast Cancer…

Primary: Number of Participants With Adverse Events — 87; 22; 1; 7 participants

Primary: Startle Potentiation During Stress Reactivity Task. — 45.7; 40.1; 33.2; 25.2 startle potentiation (μV)

Primary: Time to Next Seizure (Per Clinical Observation With Electroencephalogram [EEG] Confirmation) or Rescue Medication — NA; NA; NA hours

Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38

Primary: Change From Baseline in Lower Facial Volume Using VECTRA 3D Images — -8.20; -7.41; -6.84; -4.40 cubic centimeter (cm^3) — p=< 0.001

Primary: Change From Baseline in Tumor Size to the End of Cycle 2 — 1.06; 1.01 Log Ratio of Tumor Size — p=0.284

Primary: Overall Complete Remission Rate at Day 28 After CART-19 Therapy — 8; 10; 6; 6 Participants

Primary: Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment. — 10.8; 17.6 units on a scale

Primary: Frequency of Response — 9; 8 Number of participants

Primary: Percentage of Participants With a Favorable Microbiological Response at Completion of IV Study Therapy — 95.5; 98.6; 98.7 Percentage of Participants — p=0.005

Primary: Intraocular Pressure in mmHg — 19.01; 19.84; 18.95 Intraocular Pressure in mmHg

Primary: Efficacy of Vismodegib — 2; 5; 1; 1 tumors

Primary: Proportion of Participants With Grade 3 or Higher Adverse Events (AEs) in Cohorts 1-3 Romidepsin Arms — 0 proportion of participants

Primary: Clinical Responder Rate at Period 1: Week 16 — 10; 4 participants